Systemic treatments for mBC are selected based on multiple factors, including age, comorbidities, hormone receptor and human epidermal growth factor receptor 2 (HER2) status, previous cancer treatments, and tumor burden [3]. This evidence concerns the gene ERBB2 and cancer.